Resistance to Cycloguanil Pamoate (CI-501) by Falciparum Malaria in West Pakistan

Peter G. ContacosLaboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
Close
,
G. Robert CoatneyLaboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Close
,
Joseph S. LunnLaboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Search for other papers by Joseph S. Lunn in
Current site
Google Scholar
PubMed
Close
, and
William ChinLaboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Search for other papers by William Chin in
Current site
Google Scholar
PubMed
Close
Restricted access

Summary

The repository preparation of cycloguanil pamoate (Camolar®, CI-501) was tested therapeutically against malaria in West Pakistan. Three of the 40 villagers who were treated had recrudescences of their falciparum infections.

The parasite from one of these individuals was established in prisoner volunteers and tested for its susceptibility to various antimalarials. The results of these studies indicated that this strain of falciparum malaria was resistant to chlorguanide and pyrimethamine but susceptible to mepacrine, chloroquine, and quinine.

Author Notes

Laboratory of Parasite Chemotherapy, NIAID, NIH, Malaria Project, U. S. Penitentiary, Atlanta, Georgia.

Chief, Laboratory of Parasite Chemotherapy, NIAID, NIH, Bethesda, Maryland.

Present address: Department of Medicine, University Hospital, Syracuse, New York.

Save